Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation.
T. de Witte,F Pikkemaat,Jo Hermans,A. van Biezen,S Mackinnan,Jeroen J. L. M. Cornelissen,Alois Gratwohl,Michel Delforge,A. Iriondo,M Kuentz,J L Harousseau,Axel A. Fauser,Hannes Wandt,Runde,Dietger Niederwieser,J. F. Apperley +15 more
Reads0
Chats0
TLDR
The results of transplantation with mismatched family donors were comparable to those obtained with unrelated donor transplantation, and suggests that nonidentical family donors may be considered if a fully matched unrelated donor is not available.Citations
More filters
Journal ArticleDOI
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Luca Malcovati,Eva Hellström-Lindberg,David G. Bowen,Lionel Ades,Jaroslav Cermak,Consuelo del Cañizo,Matteo G. Della Porta,Pierre Fenaux,Norbert Gattermann,Ulrich Germing,Joop H. Jansen,Moshe Mittelman,Ghulam J. Mufti,Uwe Platzbecker,Guillermo Sanz,Dominik Selleslag,Mette Skov-Holm,Reinhard Stauder,Argiris Symeonidis,Arjan A. van de Loosdrecht,Theo de Witte,Mario Cazzola +21 more
TL;DR: Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program and Guidelines were developed on the basis of a list of patient- and therapy-oriented questions.
Journal ArticleDOI
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.
Rodrigo Martino,Simona Iacobelli,Ronald Brand,Thekla Jansen,Anja van Biezen,Jürgen Finke,Andrea Bacigalupo,Dietrich W. Beelen,J Reiffers,Agnès Devergie,Emilie Alessandrino,Ghulam J. Mufti,Renee M.Y. Barge,Jorge Sierra,Tapani Ruutu,Marc Boogaerts,Michele Falda,Jean Pierre Jouet,Dieter Niederwieser,Theo de Witte +19 more
TL;DR: Patients with no contraindications for SMC should not receive RIC outside of prospective randomized trials, which are needed to establish the position of RIC-based transplantation in the treatment of patients with MDS.
Journal ArticleDOI
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.
H. Joachim Deeg,Barry E. Storer,John T. Slattery,Claudio Anasetti,Kristine Doney,John A. Hansen,Hans-Peter Kiem,Paul J. Martin,Effie W. Petersdorf,Jerald P. Radich,Jean E. Sanders,Howard M. Shulman,Edus H. Warren,Robert P. Witherspoon,Eileen Bryant,Thomas R. Chauncey,Lisa Getzendaner,Rainer Storb,Frederick R. Appelbaum +18 more
TL;DR: A targeted BUCY regimen provided effective transplant conditioning for patients with MDS receiving transplants from HLA-identical siblings or alternative donors, and RFS tended to be superior in patients receiving transplant with peripheral blood rather than marrow stem cells.
Journal ArticleDOI
Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant.
Yangyuan Wang,Wang Hx,Yongrong Lai,Sun Zm,Depei Wu,Ming Jiang,Dai-Hong Liu,Kailin Xu,Qifa Liu,Lin Liu,Jinghua Wang,Gao F,Jian Ouyang,S J Gao,L P Xu,Xiao-Jun Huang,Xiao-Jun Huang +16 more
TL;DR: The data suggest that ISDs remain the best donor source for MDS patients while HIDs (perhaps 4–5/6 HID in particular) could be a valid alternative when an ISD is not available; human leukocyte antigen disparity had no effect on survival among the HID patients.
Journal ArticleDOI
Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome
Jun Ooi,Tohru Iseki,Satoshi Takahashi,Akira Tomonari,Koji Ishii,Kashiya Takasugi,Yoko Shimohakamada,Nobuhiro Ohno,Kaoru Uchimaru,Fumitaka Nagamura,Arinobu Tojo,Shigetaka Asano +11 more
TL;DR: The results of unrelated cord blood transplantation for 13 adult patients with advanced myelodysplastic syndrome suggest that adult advanced MDS patients without suitable related or unrelated bone marrow donors should be considered for CBT.
References
More filters
Journal ArticleDOI
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
Peter L. Greenberg,Christopher Cox,Michelle M. LeBeau,Pierre Fenaux,Pierre Morel,Guillermo Sanz,Miguel A. Sanz,Teresa Vallespi,Terry J. Hamblin,David Oscier,Kazuma Ohyashiki,Keisuke Toyama,Carlo Aul,Ghulam J. Mufti,John M. Bennett +14 more
TL;DR: The International MDS Risk Analysis Workshop combined cytogenetic, morphological, and clinical data from seven large previously reported risk-based studies that had generated prognostic systems as discussed by the authors.
Journal ArticleDOI
Proposals for the classification of the myelodysplastic syndromes.
John M. Bennett,Daniel Catovsky,Marie-Thérèse Daniel,G. Flandrin,David A. G. Galton,Harvey R. Gralnick,Harvey R. Gralnick,C. Sultan +7 more
TL;DR: It is now proposed that over 30% of bone marrow blasts will suffice for the diagnosis of acute myeloid leukaemia (AML) in any of its forms (M1‐M6) and recognition of the new category, RAEB in transformation, may throw light on the pathogenesis of AML.
Journal ArticleDOI
Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program
Nancy A. Kernan,Glenn E. Bartsch,Robert C. Ash,Patrick G. Beatty,Richard E. Champlin,Alexandra H. Filipovich,James Gajewski,John A. Hansen,Jean P. Henslee-Downey,Jeffrey McCullough,Philip B. McGlave,Herbert A. Perkins,Gordon L. Phillips,Jean E. Sanders,David F. Stroncek,E. Donnall Thomas,Karl G. Blume +16 more
TL;DR: The National Marrow Donor Program has benefited a substantial number of patients in need of marrow transplants from closely HLA-matched unrelated donors and has facilitated the recruitment of unrelated donors into the donor pool and the access to suitable marrow.
Journal ArticleDOI
Haematopoietic stem cell transplantation for patients with myelo- dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Theo de Witte,Jo Hermans,Jaak M. Vossen,Andrea Bacigalupo,Giovanna Meloni,Niels Jacobsen,Tapani Ruutu,Per Ljungman,Alois Gratwohl,Volker Runde,Dietger Niederwieser,Anja van Biezen,Agnès Devergie,Jan Cornelissen,Jean-Pierre Jouet,Renate Arnold,Jane F. Apperley +16 more
TL;DR: Allogeneic stem cell transplantation from an HLA‐identical sibling donor is a curative treatment option for a young patient with myelodysplastic syndrome, limited by age and lack of sibling donors.
Journal ArticleDOI
Age-related incidence and other epidemiological aspects of myelodysplastic syndromes
TL;DR: A strong correlation between the proportion of elderly patients and the relative frequency of MDS diagnoses is found, and there was no upward trend for AML over the study period.